IOVANCE director granted 90,316 deferred RSUs

WEISER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

WEISER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS director Michael Weiser received a grant of 90,316 deferred restricted stock units on June 16, 2026. Each unit represents one share of common stock under the 2018 Equity Incentive Plan. The units vest on the earlier of one year after the grant date or just before the next annual shareholder meeting, and delivery of shares is deferred until specific future events. Following this grant, Weiser holds 90,316 deferred restricted stock units directly.

Insider Trade Summary

Grant/Award: 90,316 shares

Grant/Award 1 txn

Insider WEISER MICHAEL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Restricted Stock Unit	90,316	$0.00	$0.00

Holdings After Transaction: Deferred Restricted Stock Unit — 90,316 contracts (Direct)

Footnotes (2)

1. F1. Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
2. F2. Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.

Key Figures

Deferred RSU grant: 90,316 units Grant price: $0.00 per unit Post-grant holdings: 90,316 units +1 more

4 metrics

Deferred RSU grant 90,316 units Granted on June 16, 2026 to director Michael Weiser

Grant price $0.00 per unit Deferred restricted stock unit award under 2018 Equity Incentive Plan

Post-grant holdings 90,316 units Deferred restricted stock units following this transaction

Outer issuance limit 10 years Latest date for share issuance from grant date

Key Terms

Deferred Restricted Stock Unit, 2018 Equity Incentive Plan, vest, change in control

4 terms

Deferred Restricted Stock Unit financial

"Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share"

2018 Equity Incentive Plan financial

"are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended)"

vest financial

"the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

change in control financial

"a change in control (as defined in the DRSU agreement)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IOVANCE BIOTHERAPEUTICS (IOVA) report for Michael Weiser?

IOVANCE BIOTHERAPEUTICS reported that director Michael Weiser received 90,316 deferred restricted stock units on June 16, 2026. These units are a stock-based compensation award, not an open-market purchase or sale, and are tied to future service-based vesting conditions.

How many IOVA deferred restricted stock units did Michael Weiser acquire in this Form 4?

Michael Weiser acquired 90,316 deferred restricted stock units in this transaction. Each unit is linked to one share of IOVANCE BIOTHERAPEUTICS common stock and was granted at a price of $0.00 under the company’s 2018 Equity Incentive Plan.

When do Michael Weiser’s IOVA deferred restricted stock units vest?

The deferred restricted stock units vest on the earlier of the first anniversary of the June 16, 2026 grant date or the day before IOVANCE BIOTHERAPEUTICS’ next annual shareholder meeting, provided Michael Weiser continues serving the company through that vesting date.

When will common shares underlying Michael Weiser’s IOVA DRSUs actually be issued?

Common shares underlying Michael Weiser’s deferred restricted stock units are issued later, not at grant. Issuance occurs upon the earliest of three months after he leaves board service, a qualifying change in control, or ten years from the June 16, 2026 grant date.

Are Michael Weiser’s IOVA deferred restricted stock units held directly or indirectly?

The Form 4 shows Michael Weiser’s 90,316 deferred restricted stock units as a direct holding. The ownership code is listed as “D,” indicating direct ownership rather than indirect ownership through an entity or trust structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 05:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEISER MICHAEL

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Restricted Stock Unit	(1)	06/16/2026		A		90,316		(2)	(2)	Common Stock	90,316	$0	90,316	D

Explanation of Responses:

1. Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).

2. Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.

	/s/ Michael Weiser	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)